According to a news release from Benchmark Plc, the marketing authorisation (MA) marks an important milestone towards optimal efficiency of the sea lice treatment. The MA allows aquaculture technicians to re-use Ectosan Vet treatment water for a second batch of fish, as long as water quality parameters are maintained to the satisfaction of the prescribing veterinarian.
“We are very pleased to have been granted a variation to the marketing authorisation from the Norwegian Medicines Agency,” Benchmark CEO Trond Wiliksen said. “Ectosan Vet and CleanTreat is a much-needed solution for the industry which continues to show excellent results with efficacy above 99 percent as well as good operational efficiency.”
The double-use strategy will increase the efficiency of treatments as a producer will be able to treat a salmon farm more efficiently with a solution that delivers more than 99 percent efficacy, promotes animal welfare, reduces mortality and protects the environment – driving sustainability in the industry.
This MA variation represents a further important step towards Benchmark’s goal of optimising the efficiency of their medicinal sea lice solutions, and further trials are ongoing to support multiple re-use of treatment water.
“It is the first medicinal solution brought to the Norwegian market in over ten years which addresses one of the biggest challenges in salmon production, while improving animal welfare, reducing mortality and protecting the environment.” Wiliksen concluded.
